NCT05029960View on ClinicalTrials.gov

Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas

EARLY_PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

May 17, 2022

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions

Brain Tumor

Interventions

DRUG

Brivaracetam

Dose of 50 mg twice daily for 6 months

Trial Locations (1)

14642

University of Rochester Medical Center, Rochester

All Listed Sponsors

lead

University of Rochester

OTHER